Journal of Cardiovascular Pharmacology and Therapeutics · 2000 · 25 citations · 57 references
MedicineCardiologyPharmacologyMolecular PharmacologyPharmacodynamicsSignal TransductionCardiac PharmacotherapyCardiovascular Molecular PhysiologyCardiovascular PharmacodynamicsCardiovascular PharmacologyHemodynamic PharmacologyIschemic Heart DiseaseAngiotensin Ii Receptor BlockersCardiac Contractile Protein RegulationCardioprotective TherapyInositol 1, 4, 5-Trisphosphate Receptor SignalingInositol 1, 4, 5-Trisphosphate ReceptorsMyocardial Ischemia-reperfusion InjuryProtein Kinase G SignalingVentricular Diastolic Function
BACKGROUND: We hypothesized that the cardioprotective effect of angiotensin II (AngII) type 1 receptor (AT(1)R) blockade during in vivo ischemia-reperfusion (IR) might be associated with an increase in AngII type 2 receptor (AT(2)R) protein, as well as 1,4,5-inositol trisphosphate type 2 receptor (IP(3)R) and protein kinase C(epsilon) (PKC(epsilon)) proteins and cyclic guanosine 3',5' monophosphate (cGMP). METHODS AND RESULTS: We studied the effects of the AT(1)R blocker, candesartan, on in vivo left ventricular (LV) systolic and diastolic function and remodeling (echocardiogram/Doppler) and hemodynamics during canine reperfused anterior infarction (90-minute ischemia, 120-minute reperfusion), and ex vivo infarct size and AT(1)R/AT(2)R, IP(3)R, and PKC(epsilon) proteins (immunoblots), and cGMP (enzyme immunoassay). Compared with controls, candesartan (1 mg/kg intravenously over 30-minute preischemia) inhibited the AngII pressor response, decreased preload and afterload, improved LV systolic and diastolic function, limited LV remodeling, decreased infarct size (55% vs 27% risk; P <.000003), markedly increased AT(2)R, IP(3)R, and PKC(epsilon) proteins in the infarct zone, but not the AT(1)R protein, and increased infarct more than noninfarct cGMP. CONCLUSIONS: The overall results suggest that cardioprotective effects of AT(1)R blockade on acute IR injury might involve AT(2)R activation and downstream signaling via IP(3)R, PKC(epsilon), and cGMP.
57
Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure
Robert S. McKelvie, Salim Yusuf, Dan Pericak et al. · Circulation · 1999 · 881 citations · Full text